Objective: To investigate the clinical efficacy of kangguzeng capsule combined with basic anti osteoporosis drugs in the treatment of postmenopausal osteoporosis. Methods: 96 patients who met the inclusion criteria in the First Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from June 2020 to June 2021 were included in the study. According to the random number table, the patients were divided into treatment group (48 cases) and control group (48 cases). The control group was treated with basic anti osteoporosis drugs, including alendronate sodium and calcitriol capsules; the treatment group was given kangguzeng Capsule on the basis of the control group. The patients were followed up regularly, and the TCM clinical syndrome score, pain visual analogue score (VAS), serum type I procollagen amino terminal propeptide (PINP) and type I collagen carboxyl terminal peptide were observed and recorded (β- CTX) and other indicators. Results: the clinical syndrome scores of the treatment group and the control group were improved. Compared with those before treatment, the clinical syndrome scores of the treatment group and the control group decreased significantly after treatment, and the difference was statistically significant (P < 0.05). The score of the treatment group was significantly better than that of the control group after treatment, and the difference was statistically significant (P < 0.05); In terms of VAS score, compared with that before treatment, the VAS score of the treatment group and the control group decreased significantly after treatment, and the difference was statistically significant (P < 0.05). The score of the treatment group after treatment was significantly better than that of the control group after treatment, and the difference was statistically significant (P < 0.05); In terms of PINP, the PINP of the treatment group and the control group were significantly higher than that before treatment (P < 0.05). The PINP of the treatment group was significantly higher than that of the control group after treatment (P < 0.05); stay β- In terms of CTX, the treatment group and the control group were compared after treatment and before treatment, β- CTX decreased significantly, and the difference was statistically significant (P < 0.05) β- CTX and control group after treatment β- There was significant difference in CTX (P < 0.05).Conclusion: kangguzeng capsule combined with basic anti osteoporosis drugs is effective in the treatment of postmenopausal osteoporosis. It can improve the clinical symptoms, biochemical indexes of bone metabolism and bone mineral density, and improve the quality of life of patients.

Zhong Yuke, Dong Bo, Yao Jie, Yuan Puwei, Liu Deyu, Kang Wulin. Clinical Efficacy of Kangguzeng Capsule Combined with Basic Anti Osteoporosis Drugs in the Treatment of Postmenopausal Osteoporosis. Frontiers in Medical Science Research (2022) Vol. 4, Issue 8: 1-6. https://doi.org/10.25236/FMSR.2022.040801.

[1] Li Xianfeng Classification and classification of osteoporosis [J]. Chinese Journal of general practice, 2005 (16): 1300.

[2] The results of the epidemiological survey of osteoporosis in China and the special action of "healthy bones" were released [J]. Chinese Journal of osteoporosis and bone mineral diseases, 2019, 12 (04): 317-318.

[3] OsterhoffG, Morgan EF, Shefelbine SJ, et al. Bone mechanical properties and changes with osteoporosis [J]. Injury, 2016, 47:S11-S20.

[4] Zhang Xuefang, Yang Xiaobin, Hao Dingjun, et al. Epidemiological characteristics of patients with thoracolumbar osteoporotic fractures [J]. Department of general medicine, China: 2019，22(11):1288- 1292.

[5] Cui L, Chen L, Xia Wet al. Vertebral fracture in postmenopausal Chinese women: a population-based study [J]. Osteoporosis Int, 2017, 28(9):1-8.

[6] SiL, Winzenberg TM, Jiang Q, et al. Projection of osteoporosis- related fractures and costs in China: 2010-2050[J] .Osteoporos Int, 2015, 26(7):1929-1937.

[7] Li Yanhong, Gong Futai, Shi Yaowu, et al Current situation and research progress of integrated traditional Chinese and Western medicine in the treatment of primary osteoporosis [J]. Chinese Journal of osteoporosis, 2017,23 (05): 690-694.

[8] Tsai JNNishiyama KKLin D,et al. Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT Study. J Bone Miner Res, 2017, 32(10):2001-2009.

[9] Sundeep Khosla, Lorenz C Hofbauer. Osteoporosis treatment: recent developments and ongoing challenges [J]. The Lancet Diabetes & Endocrinology, 2017, 5(11): 898.

[10] Wang Yong,Wang Yang. Primary osteoporosis in China: a review [J]. J Clin Endocrinol,2017,20(2): 3993-3982. 

[11] Chinese medicine diagnosis and treatment guidelines for postmenopausal osteoporosis (bone flaccidity) (2019 Edition) [J]. Traditional Chinese medicine bone setting, 2020, 32 (02): 1-13.

[12] Zheng Xiaoyu Guiding principles for clinical research of new traditional Chinese medicine (Trial) [M] Beijing: China Medical Science and Technology Press, 2002:648.

[13] Zhang Mengmeng, Zhang Xiuzhen, Deng Weimin, et al Expert consensus on clinical application of biochemical indicators of bone metabolism (2020) [J]. Chinese Journal of osteoporosis, 2020,26 (06): 781-796.

[14] Feng J, Liu S, Ma S, et al. Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-kappaB signaling pathway [J]. Acta Biochim Biophys Sin (Shanghai), 2014, 46(12):1024-1033.

[15] Pan Xinyao, Xie Xinwei, Zhou Qi, et al Research progress of traditional Chinese medicine in postmenopausal osteoporosis [J]. Chinese Journal of integrated traditional Chinese and Western medicine, 2019, 39 (09): 1140-1147.

[16] Li Jianguo, Xie Xingwen, Li Ning, et al Recognition and treatment of viscera in traditional Chinese medicine for postmenopausal osteoporosis [J]. Chinese Journal of basic medicine of traditional Chinese medicine, 2019, 25 (03): 410-412 + 420.

[17] Zhao Siyi, Huang Fan, Feng Zitong, et al Meta analysis on the efficacy and safety of traditional Chinese medicine compound preparations for tonifying the kidney and activating blood circulation in the treatment of postmenopausal osteoporosis [J]. China pharmacy, 2019, 30 (08): 1105-1111.

[18] Liu Wei, Zhang Lei, Wu Yuanzhen A randomized controlled study on 100 cases of senile osteoporosis treated by Tonifying the kidney and activating blood circulation [J] Journal of traditional Chinese medicine, 2015,56 (09): 769-772.

[19] Deng Yangyang, Sun Xin, Li Jia, et al Effects of kidney tonifying and blood activating traditional Chinese medicine on IHH mRNA and protein expression in femur and kidney of ovariectomized osteoporosis model rats [J]. Chinese Journal of traditional Chinese medicine, 2019, 34(04): 1401-1404.